SCHEMBL5486520

SCHEMBL5486520

C[C@@H]1CN(c2nccnc2C#N)CCN1C(=O)/C=C/c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.44
GRM1 Q13255 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
KIT P10721 4/20 0.40
LMNA P02545 2/20 0.40
AVPR1A P37288 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
IDH1 O75874 1/20 0.40
LIMK2 P53671 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RBP4 P02753 1/20 0.38
PIK3CD O00329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5486528 1.00 GRM5 (0.44) GRM5GRM1CYP3A4CYP2D6KIT
SCHEMBL14565982 0.90 GRM5 (0.44) GRM5CYP3A4CYP2D6LMNANPC1
SCHEMBL5476119 0.90 GRM5 (0.44) GRM5CYP3A4CYP2D6LMNANPC1
SCHEMBL5483923 0.90 GRM1 (0.42) GRM5GRM1CYP3A4CYP2D6AVPR1A
SCHEMBL5481381 0.90 GRM1 (0.42) GRM1CYP3A4CYP2D6LIMK2L3MBTL1
SCHEMBL5480190 0.90 GRM1 (0.42) GRM1CYP3A4CYP2D6LIMK2L3MBTL1
SCHEMBL5480198 0.90 GRM1 (0.42) GRM1CYP3A4CYP2D6LIMK2L3MBTL1
SCHEMBL5481392 0.90 GRM1 (0.42) GRM1CYP3A4CYP2D6LIMK2L3MBTL1
SCHEMBL5483917 0.90 GRM1 (0.42) GRM5GRM1CYP3A4CYP2D6AVPR1A
SCHEMBL14565981 0.89 SLC6A7 (0.43) GRM5LMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US claimed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists GRM5, GRM1, GRM3 GRM5 1/4885GRM1 2/4885CYP3A4 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.